Brisbane, Australia, 15 April 2019 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has submitted an application to the US Food and Drug Administration (FDA) for De Novo classification of ResAppDx-US, a mobile software application for the diagnosis of paediatric respiratory disease using cough sounds.
Respiratory disease causes a major portion of healthcare concerns in children; with cough being the most common illness-related reason for ambulatory visits in the US and among the top two principal reasons for children to visit the emergency department (ED). The single most common diagnosis from a child’s ED visit is an acute upper respiratory tract infection, with lower respiratory tract diseases also among the most frequent diagnoses.
ResAppDx-US is intended to be used by clinicians as an aid in the diagnosis of primary upper respiratory tract disease, lower respiratory tract disease and asthma/reactive airway disease. ResAppDx-US has the potential to improve diagnostic accuracy, shorten time to treatment and improve access to diagnostic testing, all using only a smartphone. The De Novo application is supported by the SMARTCOUGH-C-2 clinical study which recruited over 1,400 patients at three hospital sites in the US.
“This submission represents the culmination of years of development work and marks a significant milestone towards commercialisation,” said Tony Keating, CEO and Managing Director. “These respiratory diseases are the most common illnesses seen in healthcare, and once cleared by the FDA ResAppDx-US will deliver substantial clinical benefits by providing actionable information to clinicians sooner. We are now entering a new and exciting phase in ResApp’s evolution as we prepare for the commercial launch of ResAppDx-US.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a double-blind, prospective clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.